

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

FEBRUARY 5, 2002

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Laboratory Corporation of America -Registered Trademark-
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced
that Thomas P. Mac Mahon, chairman and chief executive
officer, is scheduled to speak at the UBS Warburg Global
Healthcare Services Conference in New York City on
Wednesday, February 6th at 3:00 p.m. Eastern Time. The
presentation will be webcast live, with a rebroadcast
available for a period of 30 days, and may be heard online
at www.labcorp.com.

At the conference, Mr. Mac Mahon will reiterate Company
guidance for 2001 and 2002, as filed in an 8-K on October
22, 2001. Mr. Mac Mahon will state, "For 2001, we expect
revenue growth of 13.5 percent, EBITDA margins of
approximately 21 percent of sales and EPS growth of
approximately 55 percent compared to 2000. For 2002, we
expect to increase overall revenues by approximately 12
percent compared to 2001 and we expect EPS growth, of
approximately 33 percent compared to 2001, before applying
the new accounting rules regarding goodwill effective
January 1, 2002. After applying the new accounting rules,
we expect the non-amortization of goodwill to have an impact
of approximately \$26 million in 2002, resulting in an
increase to EPS of approximately \$0.36."

Each of the above forward-looking statements is subject to
change based on various important factors, including without
limitation, competitive actions in the marketplace and
adverse actions of governmental and other third-party
payors. Further information on potential factors that could
affect LabCorp's financial results is included in the
Company's Form 10-K for the year ended December 31, 2000 and
subsequent SEC filings.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By:/s/ BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President
and Secretary

Date: February 5, 2002